SCHEMBL6514760

SCHEMBL6514760

COc1cc([C@@H](C)O[C]=O)c([N+](=O)[O-])cc1OCc1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.48
KMT2A Q03164 4/20 0.48
ALDH1A1 P00352 2/20 0.48
MAPT P10636 3/20 0.45
HPGD P15428 2/20 0.45
HTR1A P08908 1/20 0.45
ADRA1D P25100 1/20 0.45
ADRA1A P35348 1/20 0.45
ADRA1B P35368 1/20 0.45
ABCB1 P08183 1/20 0.43
SGMS2 Q8NHU3 1/20 0.43
CTSV O60911 3/20 0.42
CTSL P07711 3/20 0.42
POLB P06746 1/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
MYC P01106 1/20 0.39
MAX P61244 1/20 0.39
SRD5A1 P18405 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6518325 1.00 MEN1 (0.48) MEN1KMT2AALDH1A1MAPTHPGD
SCHEMBL6514763 0.86 ALDH1A1 (0.47) MEN1KMT2AALDH1A1MAPTHPGD
SCHEMBL7031532 0.85 MEN1 (0.52) MEN1KMT2AALDH1A1MAPTHPGD
SCHEMBL7031531 0.85 MEN1 (0.52) MEN1KMT2AALDH1A1MAPTHPGD
SCHEMBL7031530 0.85 MEN1 (0.52) MEN1KMT2AALDH1A1MAPTHPGD
SCHEMBL121875 0.84 CYP3A4 (0.47) MEN1KMT2AALDH1A1MAPTPOLB
SCHEMBL7031522 0.84 ALDH1A1 (0.50) MEN1KMT2AALDH1A1MAPTHPGD
SCHEMBL7031518 0.84 ALDH1A1 (0.50) MEN1KMT2AALDH1A1MAPTHPGD
SCHEMBL31756984 0.81 MEN1 (0.56) MEN1KMT2AALDH1A1MAPTHPGD
SCHEMBL10585706 0.81 MEN1 (0.56) MEN1KMT2AALDH1A1MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6489466-B2 PRODUCING IMMOBILIZED OLIGONUCLEOTIDES ON A SUBSTRATE BY COVALENTLY ATTACHING A FIRST NUCLEOTIDE OR OLIGONUCLEOTIDE VIA A C-5' OXYGEN OF THE NUCLEOTIDE TO THE SUBSTRATE; C-3'OXYGEN PROTECTED WITH PHOTO- OR CHEMICAL-LABILE GROUPS LINDEN TECHNOLOGIES, INC. 2002-12-03 US claimed
US-6855501-B2 Transfer of arrayed chemical compositions LINDEN TECHNOLOGIES, INC. (US) 2005-02-15 US disclosed
US-6838447-B2 Particulate compositions for chemical synthesis LINDEN TECHNOLOGIES, INC. (US) 2005-01-04 US disclosed
US-20040013573-A1 Polymer synthesis apparatus LINDEN TECHNOLOGIES, INC. 2004-01-22 US disclosed
US-20030013868-A1 C-3' protected monomeric nucleotides and synthesis of oligonucleotides on solid support LINDEN TECHNOLOGIES, INC., A DELAWARE CORPORATION 2003-01-16 US disclosed
US-20030009027-A1 C-3' protected monomeric nucleotides and synthesis of oligonucleotides on solid support LINDEN TECHNOLOGIES, INC., A DELAWARE CORPORATION 2003-01-09 US disclosed
US-6489466-B2 PRODUCING IMMOBILIZED OLIGONUCLEOTIDES ON A SUBSTRATE BY COVALENTLY ATTACHING A FIRST NUCLEOTIDE OR OLIGONUCLEOTIDE VIA A C-5' OXYGEN OF THE NUCLEOTIDE TO THE SUBSTRATE; C-3'OXYGEN PROTECTED WITH PHOTO- OR CHEMICAL-LABILE GROUPS LINDEN TECHNOLOGIES, INC. 2002-12-03 US disclosed
US-20020168669-A1 Patterned polymer synthesis LINDEN TECHNOLOGIES, INC. 2002-11-14 US disclosed
US-20020136772-A1 Polymer synthesis LINDEN TECHNOLOGIES, INC. 2002-09-26 US disclosed
US-20020137719-A1 Particulate compositions for chemical synthesis LINDEN TECHNOLOGIES, INC. 2002-09-26 US disclosed
US-20020136978-A1 Transfer of arrayed chemical compositions LINDEN TECHNOLOGIES, INC. 2002-09-26 US disclosed
US-20010044530-A1 C-3' protected monomeric nucleotides and synthesis of oligonucleotides on solid support LINDEN TECHNOLOGIES, INC. 2001-11-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030013868-A1 C-3' protected monomeric nucleotides and synthesis of oligonucleotides on solid support RNGTT, BCDIN3D, NT5C3B MEN1 2595/4885KMT2A 2885/4885ALDH1A1 3128/4885
US-20010044530-A1 C-3' protected monomeric nucleotides and synthesis of oligonucleotides on solid support RNGTT, BCDIN3D, NT5C3B MEN1 2595/4885KMT2A 2885/4885ALDH1A1 3128/4885
US-20030009027-A1 C-3' protected monomeric nucleotides and synthesis of oligonucleotides on solid support RNGTT, BCDIN3D, NT5C3B MEN1 2595/4885KMT2A 2885/4885ALDH1A1 3128/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.